Potential Medicinal Value of Rhein for Diabetic Kidney Disease

Chin J Integr Med. 2023 Oct;29(10):951-960. doi: 10.1007/s11655-022-3591-y. Epub 2023 Jan 6.

Abstract

Diabetic kidney disease (DKD) is the primary cause of mortality among diabetic patients. With the increasing prevalence of diabetes, it has become a major concern around the world. The therapeutic effect of clinical use of drugs is far from expected, and therapy choices to slow the progression of DKD remain restricted. Therefore, research on new drugs and treatments for DKD has been a hot topic in the medical field. It has been found that rhein has the potential to target the pathogenesis of DKD and has a wide range of pharmacological effects on DKD, such as anti-nephritis, decreasing blood glucose, controlling blood lipids and renal protection. In recent years, the medical value of rhein in the treatment of diabetes, DKD and renal disease has gradually attracted worldwide attention, especially its potential in the treatment of DKD. Currently, DKD can only be treated with medications from a single symptom and are accompanied by adverse effects, while rhein improves DKD with a multi-pathway and multi-target approach. Therefore, this paper reviews the therapeutic effects of rhein on DKD, and proposes solutions to the limitations of rhein itself, in order to provide valuable references for the clinical application of rhein in DKD and the development of new drugs.

Keywords: bioavailability; diabetic kidney disease; rhein; rhein derivatives; toxicity.

Publication types

  • Review

MeSH terms

  • Anthraquinones / therapeutic use
  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Humans
  • Kidney / pathology

Substances

  • rhein
  • Anthraquinones